Overexpression of SMYD2 has been observed in breast, pancreatic, colorectal, esophageal, blood, lung, bladder, and hepatocellular cancers (see refs. in Table 1), and SMYD2-positive tumors are often correlated with poor patient outcomes. The gene discussed is SMYD2; the disease is hepatocellular carcinoma.